---
schema_version: "secwatch.filing_event.v1"
accession: "0001599298-22-000123"
form_type: "8-K"
ticker: "SMMT"
cik: "0001599298"
company_name: "Summit Therapeutics Inc."
filed_at: "2022-11-17T23:59:59+00:00"
generated_at: "2026-06-21T16:41:47.626576+00:00"
event_type: "leadership"
sentiment: "positive"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# Summit Therapeutics appoints Dr. Alessandra Cesano to Board of Directors, effective immediately

## Summary
- Dr. Cesano brings 25 years of oncology R&D experience; previously CMO at ESSA Pharma, NanoString, and Cleave Biosciences.
- She played an instrumental role in development and approval of Vectibix® (panitumumab) for colorectal cancer.
- Appointment aligns with Summit's plan to expand pipeline into oncology; she joins Compensation and Nominating Committees.
- Dr. Cesano also serves on the board of Puma Biotechnology (NASDAQ: PBYI) and is independent under Nasdaq rules.

## SEC filing metadata
- accession: 0001599298-22-000123
- form_type: 8-K
- ticker: SMMT
- cik: 0001599298
- company_name: Summit Therapeutics Inc.
- filed_at: 2022-11-17T23:59:59+00:00
- event_type: leadership
- sentiment: positive
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1599298/000159929822000123/0001599298-22-000123-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1599298/000159929822000123/smmt-20221115.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001599298-22-000123
- JSON: https://secwatch.observer/filing/0001599298-22-000123.json
- Plain text: https://secwatch.observer/filing/0001599298-22-000123.txt

## Key facts
- Executive change
  Dr. Alessandra Cesano was elected as Director at Summit Therapeutics Inc..
  - Action: elected
  - Role: Director
  source text: Effective on November 15, 2022, the board of directors (the “Board”) of Summit Therapeutics Inc. (the “Company”) unanimously approved (i) the election of Dr. Alessandra Cesano, MD, PhD as a director of the Company and (ii) the appointment of Dr. Cesano to serve on the Compensation Committee and the Nominating and Corporate Governance Committee of the Board.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1599298/000159929822000123/0001599298-22-000123-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.